https://twitter.com/That_Hawaii_Guy
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
So basically what you guys are telling me is I'm never going to recharge in the 30's....FINE.
RATS!!! Only got 1800 bucks in before it took off...
It is a rare day when I am unhappy with a 60% pop.
Also: um, hello? It is up 60%, I'd expect a little snappy patter or excitement...
Hmmmm...basically no volume. Still up...
When they show up on Sunday talking s**t: BUY.
They may push it down. Buy the dip if there is one.
Why would they RS if they have room in the AS count?
The news here is good...except for the dilution...but they aren't just selling shares, they are using their capital structure to build a company...revs on the way...
Meantime this particular stock can't find a bottom...
Buy them while they are beat down...
Nice find...this thing could pop next week...
And you could have bought 3s yesterday intraday...
I did not because it would breaking every trading rule i have..almost put a buy in...I would have been averaging up from.oo35...exceptions lead to exceptions and making exceptions is the exact opposite of disaplined trading...even tho that was a total no brainer.
This stock sexy AF...but you trade them you don't marry them...which is why I hate this stock because I just got done lecturing my teenager about never buying a stock without knowing when you are getting out...I have no idea when I'm getting out...original plan was to dump this sexy bitch at around .04...good thing I pulled my stop loss...which JFSAG was set at .0411...might not have filled 3s...but it was down there for several hours..
It will be irresponsible not to dump half again at .08...and if it dips back buy back in, if it keeps going...oh well: you never go broke taking profits. But I have feeling this thing is going much much higher than .10...so I'm probably going to be irresponsible. BTW. .08 would be 10x where I sold half...and I generally sell all ten baggers...this however has potential to do 40x..and I wouldn't argue too hard against people saying a buck is possible. Not probable but entirely possible...
Shoulda have sold those 6s an then bought back 3s...I really felt like 625 was a top...turns out it was...but bet it runs past that next week.
It has been quite a while since I have been scared to sell a stock...
GLTYA
Trips and 17s made me all kinds of money...
The only thing in my portfolio red today...
PAOG seeking silver.
https://www.tradingview.com/symbols/OTC-PAOG/
Might be a while need to find a bottom and trade sideways for a bit first...
But yeah...I think new 52 week highs are in the future for this one...
Might have hit new highs this last time but market was against them...
Yep...entire watch lists of every kind red today, not just weed...
I lied. 96 wasn't even close...next really solid support is way down around the 60s...hopefully it doesn't go there...lol...if it does I'll be a buyer...
Bottom has to be down here somewhere; the whole sector is floundering right now.
I'm just about out of powder for this one. Buying on the way down...people always sell when they should be buying and buy when they should be selling and then whine and complain...
CBD market is just getting started. Have a friend who hates her opiates for back pain, was raised on the BS that pot is the devil (but heroine isn't apparently), who took a gummies and ended up sleeping the whole night through and woke up feeling refreshed and not hung over for the first time in years...back pain still there but could sleep and wasn't wiped out from the drug. No she is trying to get completely off the pain killers.
CBD still has a stigma from decades of mind washing regarding hemp and cannabis. She didn't think it would work. Still worked. I'm trying to get her to try FECO because that IMO won't just kill the pain but will help fix the problem. Meantime a full night's sleep goes a long way for better health...
Have a feeling next wave is higher than 1.4...
Collect shares. This thing is hugely undervalued.
Too bad they diluted TF out of this...but they did it for future revs and to build a company. UNLIKE most other OTCs that sell shares with no expectation of revs...
When I was doing DD on this I was quite amazed and checked the numbers twice...lol...so they have revs...good revs I might add, and the SP is in the toilet. Meantime I have OTCs that don't do anything (except sell shares) with more shares out and higher valuations. That's the OTC.
Hope it goes lower...LOL...shares are on sale down here...
500k to start...will be adding, especially if they take it to trips.
Chart says oversold but that doesn't mean they don't take it lower...
Get this down as far as you can!!!
(Note the three exclamation points for added emphasis.)
Babubd thinks it's going ridiculously high...hope he is right meantime I see a nickel...so the lower the better...let them take it back to trips...lol...second wave is going to be bigger than the first...
If I can recharge .0017s I most certainly will...but I think they can get into the 30s or maybe even 20's...I'm riding free shares now but depending how far down this goes I am willing to put $10k where my mouth is...worked out great last time lol...
PAOG CBD Nutraceutical Development Featured In New Video
March 04 2021 - 11:45AM
InvestorsHub NewsWire
PAO Group Inc.’s CBD-Based Nutraceutical Shows Promise In Treating COPD… And Could Create Massive Shareholder Value
March 4, 2021 -- InvestorsHub NewsWire -- via Digital Journal -- Don't let PAO Group, Inc.'s (USOTC: PAOG) stock price fool you. PAOG should be worth far more than its sub-penny share price. In fact, PAOG may be doing more than many of its mid-cap competitors in the race to find an effective non-pharmaceutical treatment for COPD. And with its RespRx acquisition combined with other programs, PAOG is indeed on pace to accelerate CBD-based studies that could bring needed therapeutic relief to millions of COPD patients.
Moreover, PAOG is a revenue-generating company after securing an 18-month deal expected to deliver $300,000 in new revenues from its cannabis cultivation subsidiary. The first receivable may be highlighted when the company provides a Q4 update. Other deals should also help drive shareholder value higher.
In February, PAOG announced an expansion of its CBD nutraceutical operations. That initiative, highlighted in a multimedia presentation, details PAOG's CBD nutraceutical development expansion plans and explained how strategic engagements with Puration, Inc. (USOTC: PURA), North American Cannabis Holdings, Inc. (USOTC: USMJ), and Alkame Holdings, Inc. (USOTC: ALKM) can accelerate growth in multiple directions.
In fact, the breadth of news is keeping investors interested in the stock, and despite recent sector-wide weakness, PAOG has been able to hold its roughly 300% share price increase since the start of the year.
The trend higher is likely to continue when risk makes its way back into the markets. At current share prices, the opportunity may be significant.
Video Link: https://www.youtube.com/embed/p48PfDlIABQ
Targeting COPD With CBD-Based Therapeutics
The bullish trend started after PAOG announced accelerating its initiatives to develop CBD alternatives to treat patients with symptoms associated with Chronic Obstructive Pulmonary Disorder (COPD). Investor interest spiked appreciably after PAOG announced its potentially transformative acquisition of RespRx from Kali-Extracts, Inc. That asset is a good one, and more importantly, can be commercialized to target multiple indications where a better and safer standard of care is needed.
And not only does RespRx add substantial value to its product pipeline arsenal, but it also positions PAOG to soon monetize its opportunities through commercialization, licensing, or partnerships. Each option can add substantial value.
Keep in mind, too, the acquisition of RespRx does more than position PAOG as a viable competitor in the medical-grade cannabis treatment sector to treat COPD. It also allows them to leverage a patented cannabis extraction method that could be useful across many diseases. Thus, near-term revenue creation could be achieved through a licensing strategy.
Moving into 2021, its COPD initiatives may be taking the lead, but PAOG is far from being a one-shot company. In fact, PAOG has positioned itself for multiple shots on goal by advancing a nutraceutical product line that they believe will compete effectively against already marketed, higher-priced brands. During 2020, PAOG entered into several deals designed to monetize assets in the coming quarters.
Nutraceuticals Can Be A Significant Opportunity
To strengthen PAOG's development-stage program intending to deliver a pharmaceutical-grade nutraceutical COPD treatment to market, PAOG recently announced engaging with the Puerto Rico Consortium for Clinical Investigation (PRCCI) to assist with developing its proprietary Cannabidiol (CBD) extract into a nutraceutical product. The excellent news for PAOG is that the agreement not only adds credibility and sector expertise to the initiative it can help expedite approval if the two successfully develop an effective CBD-based treatment to target COPD's debilitating effects.
Moreover, with PAOG's CBD-based treatment having the potential to replace addictive and often harmful prescription drugs, the company hopes that after proving its therapeutic value can earn fast-track approval processes through regulatory agencies accepting CBD and cannabinoid compounds as viable and effective treatment options. And don't think that "big pharma" is not paying attention to the encroachment. Earlier this year, Jazz Pharmaceuticals' (NASDAQ: JAZZ) purchased GW Pharma (NASDAQ: GWPH) for $7.2 billion and set the stage for further industry consolidation. And who are the attractive targets? Small companies with compelling assets...and PAOG meets that standard.
In addition to its assets, patents, and active programs, PAOG has something that most micro-cap companies can't claim- REVENUES. And effective management of revenues can lead to even more.
Maximizing Revenues For Growth
As noted, PAO Group is doing what most of its peers are not doing...generating revenues. And if the company can maximize that income by capitalizing on new opportunities to expand its product portfolio, the $300,000 deal may pale compared to future engagements. Progress is already showing.
PAO Group recently announced a deal with Alkame Holdings Inc. (OTC PINK: ALKM) to develop and distribute its CBD nutraceuticals. Alkame adds strength to development-stage companies by adding expertise on the essential logistical side of the operations. In other words, PAOG is banking on successful product development and is putting its distribution infrastructure in place now.
That deal does more than help push revenues toward the bottom line. It also introduced PAOG to North American Cannabis Holdings, Inc. (OTC Pink: USMJ), which is expected to take on the distributor's role. The read-between-the-lines moment is that in reasonably quick succession, PAOG aligned itself with two other sector companies that add a specific skill set. Moreover, with all three actively making deals to expand their own market presence, consolidation and additional value-generating agreements among the three is likely over the coming quarters.
Thus, a sum of the parts analysis indicates on almost any measure that this emerging develop-stage company is substantially undervalued. And with shares trading at sub-penny prices per share, there are justifiable reasons for investors to take an interest in the stock.
In particular, increasing revenues, accretive deals, and access to a patented CBD extraction technology each add an independent layer of value. Stocks trading 10X higher lack the assets at PAOG, and most have far less in development. But, being under-the-radar has its drawbacks, and PAOG is hard at work to change that view.
Growth In 2021 Is Happening Already
Updates from PAOG tell a story of growth and program development. They are making strategic deals with industry companies to help expedite their near-term plans, they are generating revenues, and are positioned to leverage its patented CBD extraction process to capitalize on substantial market opportunities.
Therefore, from any valuation model, the current share price does not fairly reflect the inherent value in the PAOG product portfolio or pipeline. Moreover, by factoring in what the company can do in the next 3-12 months, inclusive of its deal with PRCCI that can accelerate product commercialization, PAOG is fueled and ready to create shareholder value.
Thus, the coming quarters can produce transformative value-creation at PAOG. And for the high-risk, high-reward investor, taking a position in PAO Group at these levels may also help transform one's investment portfolio.
Disclaimers: Hawk Point Media is responsible for the production and distribution of this content. Hawk Point Media is not operated by a licensed broker, a dealer, or a registered investment adviser. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. Our reports/releases are a commercial advertisement and are for general information purposes ONLY. We are engaged in the business of marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The information made available by Hawk Point Media is not intended to be, nor does it constitute, investment advice or recommendations. The contributors may buy and sell securities before and after any particular article, report and publication. In no event shall Hawk Point Media be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or made available by Hawk Point Media, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Hawk Point Media was compensated three-thousand-five-hundred-dollars by wire transfer to produce research, video, email, newsletters, and editorial commentary for PAO Holdings Group, Inc.. by a third party. Past performance is a poor indicator of future performance. The information in this video, article, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. Hawk Point Media strongly urges you conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D.
The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results.Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investors investment may be lost or impaired due to the speculative nature of the companies profiled.
Media Contact
Company Name: Hawk Point Media
Contact Person: Jake Ellis
Email: Send Email
City: Miami Beach
State: Florida
Country: United States
Website: https://www.greenlightstocks.com
Source: http://www.digitaljournal.com/pr/4991241#ixzz6oA3EbnEq
SOURCE: Digital Journal
I think its officially oversold...
LOL!!!
Remind me not to invite you over for dinner...LOL!!!
Selling 44s was a great idea after all...
Looking like might be time to get back in...bottom is either in or close to it...
Could plunge all the way down to 2s...if it goes under .002 BUY.
Up 159% today...
Canamex Gold Corp Common Shares (PC)
OTC BBN : CNMXF
$0.0259 0.01 (+159.00%)
Imagine if they had released this news on a day that wasn't so bloody...might have popped over 100%...
Most of my watch lists are straight red from top to bottom if they are green they are not even up 3%...LOL
And then there is this...have one other stock that was up today but missed that wave and it was up over 100%...
Still hasn't found a bottom...just when you thought it couldn't go any lower...shave off another 19%...
Bulls climb the stairs but bears jump out the window...
Took weeks to get those gains hours to lose them...wipe out.
Annoying, but my shares are free, should have sold 6s and bought back in down here lol...
Was not expecting an end of day sell off with this one...
Market is expecting "events" to unfold over the next few days...but it will positive in the end...
If you managed to buy any 3s today you are already having a good day.
Meantime most of my watch lists are RED today as well as my portfolio...except for one of which I barely own any shares...and of course it's up over 70%...other than that it's red...even SOAN.
Wish I had more shares...lol...quite the pop...
Red day in the market so to see this much green here is nice...most of my watch lists and portfolio are RED today...
Good. Don't let the door hit you on the ass.
Yep, there's even more money sloshing around and soon to be even more than that once all the money from the "stimulus" gets released and will need laundering...I think that was just the warm up...
Looks like it may settle into a trading range for a bit...5 to 10 is a heck of a spread...could break out could break down....right now very hard to call...so I'll just watch.
Low float says when it does move it could move sharply...like multi days of 20% or more, punctuated with sharper spikes...
LOL...I'm just watching for now...but the 90 million float is what got me here...
Don't kid yourselves tho, there's always shares...mms will print them out of thin air if they have to in order to make the markets...
But the last low floater I got in on, I got 20x even after correcting a bit the last few days...took quite a few months but it was worth the wait. Hopefully this runs hard too...but it is the OTC and wild swings are not at all uncommon even when board sentiment and chatter is positive. Most boards are dead. At leaste this one has posts...lol...
51 turned out to be solid support.
But I don't like it up here...too much possibility for retrace. Today's run up is very bullish, running past the top of the old shoulder. And it did it on decent volume...
Anyhow watching for now...
No, but I will...
It's called finding a bottom...
Has to be a bottom down here somewhere...
Correction at last...sideways would be nice...that was one hell of a run all the way past 6...
Now if it builds a base around 4 or 5, next run should be just as epic.
Was buy on the rumor sell on the news...lol...but that PR and news was not enough to account for all this...
I'm looking to get shares under 3...not 5.
Looks like it found a bottom. 10
Should churn sideways a bit down here that was quite a spike...shows where it could go with volume and the right news...
Nice bounce off the support at 51...good timing on that PR.
Still say it has some correcting to do...could hold up here but downside risk is still pretty high...